Botulinum Neurotoxins as Two-Faced Janus Proteins.

Area of Science:

• Neuroscience
• Toxicology
• Microbiology

Background:

• Botulinum neurotoxins (BoNTs) are potent neurotoxins produced by anaerobic bacteria.
• They inhibit acetylcholine release, causing flaccid paralysis and are among the most poisonous natural substances.
• BoNTs exist in multiple serotypes and subtypes, with botulism presenting as descending symmetric flaccid paralysis regardless of contamination route.

Purpose of the Study:

• To review the dual nature of botulinum neurotoxins as both dangerous toxins and therapeutic agents.
• To discuss current and emerging treatments for botulism and BoNT-related conditions.
• To highlight the potential of novel therapeutic strategies targeting neurotoxin inactivation.

Main Methods:

• Literature review of botulinum neurotoxin synthesis, mechanism of action, and clinical manifestations.
• Analysis of current therapeutic applications, including spastic conditions, chronic migraine, hyperhidrosis, and cosmetic uses.
• Evaluation of existing and experimental antidotes and preventative measures, including immunoglobulins, nanobodies, and small-molecule inhibitors.

Main Results:

• Botulinum neurotoxins induce transient paralysis, a characteristic exploited for therapeutic purposes.
• Approved treatments for botulism include specific immunoglobulins, with nanobodies and Ebselen showing potential for broader efficacy.
• The neurotoxin's risks and benefits have led to its description as a "two-faced Janus protein".

Conclusions:

• Botulinum neurotoxins present a significant challenge due to their toxicity but offer valuable therapeutic applications.
• Current treatments for botulism are limited, emphasizing the need for novel approaches.
• Emerging therapies like nanobodies and Ebselen hold promise for improved management of botulism and related conditions, irrespective of neurotoxin serotype.